Recruiting
Phase 1
Phase 2

Semaglutide

Sponsor:

University of Pennsylvania

Code:

NCT05746039

Conditions

Obesity

Interstitial Lung Disease

Chronic Obstructive Pulmonary Disease

Sarcoidosis, Pulmonary

Pulmonary Hypertension

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Semaglutide Pen Injector

Study Details

Brief summary:

The goal of this clinical trial is to learn whether semaglutide, an FDA-approved treatment for diabetes and obesity, is feasible and tolerable in patients with advanced lung disease.

The main question\[s\] it aims to answer are:

1. Are patients with advanced lung disease able to tolerate semaglutide therapy?
2. Are we able to titrate semaglutide therapy to a target weight?

Participants will be asked to perform pulmonary function, physical function and body composition testing, as well as a blood draw before and after 12-weeks of semaglutide therapy. While on therapy, subjects will be surveyed regarding any adverse events or side effects.

Conditions

Obesity

Interstitial Lung Disease

Chronic Obstructive Pulmonary Disease

Sarcoidosis, Pulmonary

Pulmonary Hypertension

Study ID

NCT05746039

Start date

Jan 29, 2024

Status verified date

Apr, 2026

Completion date

Dec 28, 2027

Anticipated

Primary completion date

Dec 28, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Diagnosis of one of the following lung diseases: interstitial lung disease, sarcoidosis, chronic obstructive pulmonary disease, or pulmonary hypertension
  • Age > 18
  • BMI > 30 kg/m2
  • Requires supplemental oxygen on exertion
  • Stable treatment regimen X 90 days
  • Use of disease-modifying therapy

Exclusion Criteria:

  • Diabetes
  • Pregnant or Breastfeeding
  • Recent weight loss
  • Recent or chronic GI complaints
  • History of gastroparesis
  • History of scleroderma
  • Hospitalized at time of evaluation
  • Use of weight loss medication in last 90 days
  • Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia (type 2)
  • Uncontrolled thyroid disease
  • History of acute/chronic pancreatitis
  • Prior suicide attempt
  • Suicidal ideation in last 90 days
  • Presence of a pacemaker or defibrillator

Study Design

Enrollment

8 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Study Drug (semaglutide)

Semaglutide Pen Injector 1.0 mg weekly Once weekly subcutaneous injection Other Name: Wegovy

Interventions

Semaglutide Pen Injector

Once weekly subcutaneous injection

Primary outcome measure

  • Tolerability [ Time Frame: 12 weeks ]

Central Contacts and Locations

Central contacts

Michaela R Anderson, MD

215-662-3202michaela.anderson@pennmedicine.upenn.edu

Locations

University of Pennsylvania Perelman School of Medicine

Recruiting

Philadelphia, Pennsylvania, United States, 19104

Contacts

Apurva Raje

apurva.raje@pennmedicine.upenn.edu

More Information

Sponsor

University of Pennsylvania

Last update posted

Apr 21, 2026

Last verified

Apr, 2026

Keywords

  • semaglutide

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by University of Pennsylvania on 2026-04-21.